文献速递前列腺癌

阿托伐他汀对比安慰剂用于根治性前列腺切除术前前列腺癌的随机双盲安慰剂对照临床试验

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
PubMed 文献 · Eur Urol · 2018-07-18

一项随机双盲安慰剂对照试验纳入160例未使用过他汀且计划行根治性前列腺切除术的前列腺癌患者,随机接受每日80mg阿托伐他汀或安慰剂中位27天。总体而言,阿托伐他汀未显著降低肿瘤增殖指数Ki-67或血清PSA;亚组分析中,至少使用28天后Ki-67较安慰剂降低14.1%(p=0.056),高级别病例PSA中位变化-0.6 ng/ml(p=0.024)。

要点

  • 总体阿托伐他汀未显著降低前列腺癌Ki-67或PSA。
  • 至少用药28天后Ki-67较安慰剂降低14.1%(p=0.056)。
  • 高级别病例中阿托伐他汀降低PSA,中位变化-0.6 ng/ml(p=0.024)。

核心结论

  • 总体阿托伐他汀未显著降低前列腺癌增殖指数Ki-67或血清PSA。
  • 探索性分析提示至少用药28天后可能获益,需进一步研究验证。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,纳入160例未使用过他汀且计划行根治性前列腺切除术的前列腺癌患者。
  • 随机接受每日80mg阿托伐他汀或安慰剂,从入组至手术中位27天,158例完成随访,依从性96%。

主要发现

  • 总体阿托伐他汀未显著降低Ki-67或PSA。
  • 至少使用阿托伐他汀28天后,Ki-67较安慰剂降低14.1%(p=0.056)。
  • 高级别病例(ISUP Gleason分级3级或更高)中,阿托伐他汀较安慰剂降低PSA:中位变化-0.6 ng/ml(p=0.024)。
  • 前列腺内炎症在两个研究组间无差异(p=0.8)。

临床怎么用

  • 不应基于本试验结果常规使用阿托伐他汀来降低前列腺癌增殖或PSA。
  • 至少28天用药及高级别病例的探索性获益需进一步研究验证。

局限性

  • 总体结果为阴性,亚组分析为事后探索性分析。
  • 中位用药时间仅27天,随访至手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We tested whether intervention with atorvastatin affects the prostate beneficially compared with placebo in men with prostate cancer in a randomized clinical trial. A total of 160 statin-naïve prostate cancer patients scheduled for radical prostatectomy were randomized to use 80mg atorvastatin or placebo daily from recruitment to surgery for a median of 27 d. Blinding was maintained throughout the trial. In total, 158 men completed the follow-up, with 96% compliance. Overall, atorvastatin did not significantly lower tumor proliferation index Ki-67 or serum prostate-specific antigen (PSA) compared with placebo. In subgroup analyses, after a minimum of 28 d of atorvastatin use, Ki-67 was 14.1% lower compared with placebo (p = 0.056). Among high-grade cases (International Society of Urological Pathology Gleason grade 3 or higher), atorvastatin lowered PSA compared with placebo: median change -0.6 ng/ml; p = 0.024. Intraprostatic inflammation did not differ between the study arms (p = 0.8). Despite a negative overall result showing no effect of statins on Ki67 or PSA overall, in post hoc exploratory analyses, there appeared to be benefit after a minimum duration of 28 d. Further studies are needed to verify this. PATIENT SUMMARY: Cholesterol-lowering atorvastatin does not lower prostate cancer proliferation rate compared with placebo overall, but exploratory analyses suggest a benefit in longer exposure.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Murtola TJ, Syvälä H, Tolonen T, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol. 2018. PMID: 30031572. doi:10.1016/j.eururo.2018.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。